Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CRSP | 44.44% | $3.27B | -39.52% | 0.00% |
DAN | 43.46% | $1.70B | -10.34% | 3.30% |
PLRX | 42.50% | $683.99M | -36.17% | 0.00% |
BEAM | 41.59% | $1.93B | -7.17% | 0.00% |
PTCT | 39.86% | $3.22B | +46.09% | 0.00% |
FLGT | 39.80% | $523.95M | -35.26% | 0.00% |
WOOF | 39.44% | $1.05B | +38.04% | 0.00% |
KN | 39.39% | $1.72B | +17.18% | 0.00% |
AIN | 39.34% | $2.53B | -7.48% | 1.28% |
CNDT | 39.12% | $634.76M | +13.75% | 0.00% |
SLAB | 38.84% | $4.32B | +12.08% | 0.00% |
VSH | 38.22% | $2.18B | -27.86% | 2.42% |
SCVL | 37.70% | $822.85M | +17.87% | 1.72% |
TBI | 37.61% | $219.92M | -46.40% | 0.00% |
HSII | 37.28% | $928.22M | +67.70% | 1.29% |
COHU | 37.13% | $1.12B | -25.05% | 0.00% |
NEP | 37.05% | $1.57B | -39.67% | 20.83% |
ADNT | 37.03% | $1.48B | -46.70% | 0.00% |
KFRC | 36.53% | $1.06B | -15.35% | 2.64% |
SCSC | 36.22% | $1.17B | +33.82% | 0.00% |
Finnhub
Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 millionNovocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on...
Finnhub
BAAR, Switzerland - Novocure announced today that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025.Ashley Cordova, Chief Executive...
Yahoo
Piper Sandler raised the firm’s price target on Novocure (NVCR) to $42 from $28 and keeps an Overweight rating on the shares. The firm thinks the catalyst path for Novocure shares screens more favorably for medical technology investors that can better handicap upcoming “medtech-like” milestones for the company, including new indication commercialization, regulatory submission and approvals, and securing payer coverage. Piper introduced estimates through 2028 and highlights the company’s improved
Yahoo
Cancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum was helped by price target increases from analysts. According to data compiled by S&P Global Market Intelligence, those bullish market players propelled the stock nearly 33% higher week to date as of early Friday morning.
Yahoo
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. Novocure (NASDAQ: NVCR) and its international partner Zai Lab (NASDAQ: ZLAB) announced successful top-line results from the Panova-3 study on Dec. 2, 2024. In a nutshell, it showed that the company's electric field-generating devices can improve pancreatic cancer patients' odds of survival.
SeekingAlpha
NovoCure's TTFields therapy, combined with standard chemotherapy, improves overall survival in advanced pancreatic cancer. Check out my plan on NVCR stock.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -14.27% | $20.24B | +5.28% | 1.22% |
COP | -13.17% | $135.67B | -3.29% | 2.78% |
TRGP | -12.05% | $43.91B | +144.01% | 1.35% |
ETR | -12.03% | $33.26B | +50.66% | 5.86% |
SOC | -11.30% | $2.04B | +84.05% | 0.00% |
PG | -10.23% | $376.19B | +6.64% | 2.48% |
BHC | -10.13% | $2.75B | -10.95% | 0.00% |
HUSA | -9.64% | $21.33M | 0.00% | 0.00% |
CLX | -9.63% | $19.68B | +10.78% | 3.03% |
TTE | -9.23% | $131.27B | -10.73% | 5.81% |
ROOT | -8.96% | $1.28B | +833.00% | 0.00% |
NNE | -8.86% | $705.61M | +434.50% | 0.00% |
PGR | -8.78% | $140.45B | +42.23% | 2.39% |
STG | -8.73% | $28.93M | -36.25% | 0.00% |
ALL | -8.02% | $49.47B | +23.31% | 1.94% |
CME | -7.86% | $83.51B | +16.68% | 4.47% |
KNTK | -7.07% | $3.70B | +87.13% | 4.78% |
FATBB | -7.03% | $80.60M | -15.34% | 11.94% |
TKO | -6.90% | $11.62B | +86.03% | 0.00% |
SU | -6.05% | $50.00B | +24.36% | 4.01% |
Current Value
$27.051 Year Return
Current Value
$27.051 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FENG | 0.01% | $12.87M | +59.95% | 0.00% |
WWD | -0.02% | $10.94B | +35.12% | 0.53% |
MPC | -0.03% | $48.02B | -3.05% | 2.24% |
ALAR | -0.06% | $72.34M | -10.37% | 0.00% |
PRPO | 0.08% | $8.98M | +14.99% | 0.00% |
LITB | -0.08% | $20.04M | -82.86% | 0.00% |
ED | 0.10% | $30.96B | -2.39% | 3.68% |
NBIX | -0.11% | $14.12B | +5.20% | 0.00% |
PCVX | 0.11% | $9.74B | +26.54% | 0.00% |
KEP | 0.11% | $8.86B | -3.63% | 0.00% |
NEXA | -0.13% | $821.12M | -10.92% | 0.00% |
K | 0.14% | $28.07B | +50.41% | 2.78% |
KO | -0.19% | $267.26B | +3.42% | 3.11% |
NERV | 0.19% | $14.86M | -69.42% | 0.00% |
OMAB | 0.19% | $3.22B | +5.24% | 6.12% |
CNTY | 0.20% | $89.29M | -32.17% | 0.00% |
GOGL | -0.21% | $1.87B | -8.53% | 12.86% |
FF | 0.22% | $228.44M | +32.37% | 4.53% |
FDUS | 0.25% | - | - | 8.12% |
CPNG | -0.25% | $39.52B | +43.22% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ARKG | 46.44% | $1.09B | 0.75% |
XHE | 45.30% | $217.42M | 0.35% |
GNOM | 43.76% | $68.90M | 0.5% |
RZV | 39.99% | $236.34M | 0.35% |
XRT | 39.69% | $407.30M | 0.35% |
IJS | 39.59% | $7.39B | 0.18% |
SLYV | 39.50% | $3.88B | 0.15% |
ARKK | 39.38% | $6.14B | 0.75% |
SPSM | 39.19% | $12.16B | 0.03% |
IJR | 39.13% | $86.08B | 0.06% |
VIOO | 38.97% | $3.05B | 0.1% |
VIOV | 38.97% | $1.39B | 0.15% |
PRFZ | 38.92% | $2.51B | 0.39% |
VTWO | 38.55% | $12.12B | 0.1% |
RWJ | 38.54% | $1.74B | 0.39% |
IWM | 38.44% | $70.21B | 0.19% |
QCLN | 38.44% | $549.73M | 0.59% |
GSSC | 38.39% | $520.51M | 0.2% |
IBB | 38.18% | $6.41B | 0.45% |
CALF | 38.14% | $7.87B | 0.59% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VRP | -0.18% | $1.89B | 0.5% |
CORN | 0.25% | $65.39M | 0.2% |
BILZ | -0.45% | $616.87M | 0.14% |
IYK | 0.67% | $1.21B | 0.4% |
YOLO | 0.69% | $30.32M | 1.03% |
CNBS | -0.71% | $12.05M | 0.77% |
FTXN | 0.71% | $166.21M | 0.6% |
IEO | 0.76% | $605.94M | 0.4% |
RSPG | 0.77% | $549.42M | 0.4% |
UDN | 0.80% | $47.06M | 0.78% |
TBLL | -0.93% | $2.00B | 0.08% |
IXC | -1.03% | $1.97B | 0.41% |
XLE | -1.05% | $33.71B | 0.09% |
BOXX | -1.05% | $4.73B | 0.1949% |
SGOV | 1.06% | $31.15B | 0.09% |
JUCY | -1.13% | $298.75M | 0.6% |
XLU | 1.16% | $16.40B | 0.09% |
FLOT | -1.17% | $7.88B | 0.15% |
IYE | 1.20% | $1.33B | 0.39% |
KMLM | -1.29% | $333.89M | 0.9% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -17.55% | $195.31M | 0.85% |
CTA | -11.47% | $536.34M | 0.76% |
DBE | -7.69% | $50.63M | 0.77% |
EQLS | -7.28% | $8.93M | 1% |
TAIL | -6.99% | $65.48M | 0.59% |
USCI | -6.91% | $200.39M | 1.07% |
DBO | -5.71% | $228.06M | 0.77% |
COMT | -5.54% | $717.70M | 0.48% |
DBA | -5.07% | $812.87M | 0.93% |
PDBC | -4.98% | $4.29B | 0.59% |
AGZD | -4.35% | $142.77M | 0.23% |
MSOS | -4.35% | $461.32M | 0.83% |
FTGC | -4.12% | $2.33B | 1.02% |
GSG | -3.94% | $1.07B | 0.75% |
DBC | -3.36% | $1.35B | 0.87% |
USDU | -3.23% | $390.63M | 0.5% |
BCI | -2.65% | $1.36B | 0.26% |
UUP | -2.44% | $640.67M | 0.77% |
SOYB | -2.27% | $26.14M | 0.22% |
MINT | -2.13% | $12.01B | 0.35% |